ClearPoint Neuro (CLPT)
(Delayed Data from NSDQ)
$11.88 USD
+0.51 (4.49%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $11.86 -0.02 (-0.17%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum C VGM
Balance Sheet
Fiscal Year End for ClearPoint Neuro, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 23 | 37 | 54 | 20 | 6 |
Receivables | 3 | 3 | 2 | 2 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 8 | 9 | 5 | 3 | 3 |
Other Current Assets | 2 | 2 | 1 | 0 | 0 |
Total Current Assets | 36 | 51 | 62 | 25 | 10 |
Net Property & Equipment | 1 | 1 | 1 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 1 | 1 | 1 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 43 | 55 | 66 | 30 | 12 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 0 | 0 | 0 | 0 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 5 | 3 | 2 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 3 | 1 | 1 | 1 | 1 |
Total Current Liabilities | 7 | 7 | 5 | 3 | 4 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 0 | 0 | 0 | 0 |
Convertible Debt | 10 | 10 | 10 | 0 | 2 |
Long-Term Debt | 0 | 0 | 0 | 21 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 21 | 19 | 17 | 27 | 7 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 193 | 187 | 182 | 122 | 117 |
Retained Earnings | -172 | -150 | -134 | -120 | -113 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 21 | 37 | 49 | 2 | 5 |
Total Liabilities & Shareholder's Equity | 43 | 55 | 66 | 30 | 12 |
Total Common Equity | 21 | 37 | 49 | 2 | 5 |
Shares Outstanding | 24.60 | 24.50 | 23.60 | 17.00 | 15.20 |
Book Value Per Share | 0.86 | 1.51 | 2.07 | 0.14 | 0.30 |
Fiscal Year End for ClearPoint Neuro, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 33 | 35 | 23 | 24 | 26 |
Receivables | 3 | 3 | 3 | 2 | 3 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 8 | 8 | 8 | 9 | 9 |
Other Current Assets | 2 | 2 | 2 | 2 | 2 |
Total Current Assets | 47 | 48 | 23 | 37 | 41 |
Net Property & Equipment | 2 | 1 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 53 | 54 | 23 | 44 | 48 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 10 | 10 | 0 | 0 | 0 |
Accounts Payable | 1 | 1 | 0 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 3 | 4 | 3 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 1 | 3 | 1 | 1 |
Total Current Liabilities | 17 | 15 | 7 | 6 | 6 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 1 | 1 | 0 |
Convertible Debt | 0 | 0 | 10 | 10 | 10 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 20 | 19 | 21 | 20 | 20 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 213 | 211 | 193 | 192 | 190 |
Retained Earnings | -181 | -177 | -172 | -168 | -163 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 32 | 35 | 21 | 24 | 27 |
Total Liabilities & Shareholder's Equity | 53 | 54 | 43 | 44 | 48 |
Total Common Equity | 32 | 35 | 21 | 24 | 27 |
Shares Outstanding | 27.40 | 27.00 | 24.60 | 24.60 | 24.50 |
Book Value Per Share | 1.17 | 1.28 | 0.86 | 0.98 | 1.12 |